MR-proADM dosage: Dosage of MR proADM at OLT/KT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U
Study summary
To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Kidney transplant recipient at our Institution
* Liver transplant recipient at our Institution
Exclusion Criteria:
* Re-transplantation
* Dual kidney transplantation
* Combined transplant (kidney-liver, kidney-pancreas)
* Autoimmune disease as indication to transplant
Primary outcome measure(s)
Accuracy of MR-proADM as biomarker of DGF and AR in OLT/KT — 3 years To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation.
Trial sites (1)
Facility
City
Region
Status
University of Rome Tor Vergata
Rome
Italy
Recruiting
More University of Rome Tor Vergata trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
